IRIS
FORMISANO, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.295
EU - Europa 2.856
NA - Nord America 2.217
SA - Sud America 384
AF - Africa 94
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.855
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.125
SG - Singapore 1.663
RU - Federazione Russa 1.296
IT - Italia 854
CN - Cina 827
BR - Brasile 303
HK - Hong Kong 265
VN - Vietnam 244
DE - Germania 202
NL - Olanda 110
IN - India 104
FI - Finlandia 102
CA - Canada 58
GB - Regno Unito 56
FR - Francia 52
KR - Corea 51
IE - Irlanda 48
AR - Argentina 44
CI - Costa d'Avorio 43
UA - Ucraina 26
SE - Svezia 24
MX - Messico 22
JP - Giappone 21
PK - Pakistan 21
PL - Polonia 21
ZA - Sudafrica 18
BE - Belgio 15
AT - Austria 13
TR - Turchia 13
ES - Italia 12
IQ - Iraq 12
ID - Indonesia 11
BD - Bangladesh 10
VE - Venezuela 10
LT - Lituania 9
MY - Malesia 9
EC - Ecuador 8
EG - Egitto 7
IR - Iran 7
TN - Tunisia 7
UZ - Uzbekistan 7
AU - Australia 6
CL - Cile 6
PY - Paraguay 6
CO - Colombia 5
IL - Israele 5
MA - Marocco 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
GR - Grecia 3
MK - Macedonia 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BZ - Belize 2
ET - Etiopia 2
GE - Georgia 2
GT - Guatemala 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
YT - Mayotte 2
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KN - Saint Kitts e Nevis 1
LB - Libano 1
MN - Mongolia 1
MT - Malta 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SD - Sudan 1
SN - Senegal 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
ZM - Zambia 1
Totale 8.855
Salva come PNG Salva come JPEG
Città #
Singapore 800
Moscow 300
Naples 299
Hefei 280
Hong Kong 265
Beijing 226
Ashburn 220
Chandler 204
Dallas 177
Santa Clara 121
Napoli 103
Ho Chi Minh City 94
Munich 87
Amsterdam 85
San Jose 58
Kochi 50
Seoul 50
Los Angeles 49
Hanoi 46
Millbury 45
Turku 45
Redondo Beach 41
Boston 37
Buffalo 37
Des Moines 37
New York 36
Helsinki 33
Hicksville 32
Nanjing 31
São Paulo 28
Princeton 27
Rome 26
The Dalles 26
Lawrence 24
Falkenstein 23
Pune 21
Seattle 19
Tokyo 19
Montreal 18
Nuremberg 18
San Mateo 18
Brooklyn 17
Chicago 16
Dong Ket 16
Houston 16
Toronto 16
Warsaw 16
Wilmington 16
Frankfurt am Main 14
Ottawa 14
Caserta 13
Formia 13
Milan 13
Stockholm 13
Dublin 12
Lahore 12
Orem 12
London 11
Salt Lake City 11
Biên Hòa 10
Brussels 10
Haiphong 10
Hebei 10
Mexico City 10
Nanchang 10
Casoria 9
Council Bluffs 9
Denver 9
Ninh Bình 9
Turin 9
Woodbridge 9
Da Nang 8
Johannesburg 8
Modica 8
Poplar 8
Porto Alegre 8
Redwood City 8
Tianjin 8
Afragola 7
Ankara 7
Belo Horizonte 7
Changsha 7
Guangzhou 7
Kuala Lumpur 7
Palma Campania 7
Rio de Janeiro 7
Angri 6
Boardman 6
Chennai 6
Curitiba 6
Düsseldorf 6
Guayaquil 6
Manchester 6
Phoenix 6
Pomigliano d'Arco 6
Pozzuoli 6
Salerno 6
Shanghai 6
Tunis 6
Atlanta 5
Totale 4.715
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 178
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 149
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 137
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 137
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 135
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 130
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 129
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 127
Mechanisms of resistance to mTOR inhibitors 127
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 124
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 124
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 123
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 122
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 122
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 122
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 122
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 122
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 121
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 119
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 118
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 117
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 116
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 114
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 114
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 113
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 113
Prevention of cardiovascular complications in elderly cancer patients 113
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 112
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 112
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 112
Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases 112
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 110
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 110
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 110
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 109
Mechanisms of lapatinib resistance in HER2-driven breast cancer 109
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 108
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 107
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 106
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 106
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 105
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. 105
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma 104
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. 104
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 104
From biology to therapy: Improvements of therapeutic options in Lung cancer 102
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 101
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 101
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 100
The broad spectrum of cardiotoxicities from immunotherapies 99
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 99
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 98
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 96
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 96
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer 95
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 93
Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer 92
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 91
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 89
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 88
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 86
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 86
Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. 85
INHIBITION OF CANCER CELL GROWTH AND INVASION BY TARGETING C-SRC IN BREAST CANCER MODELS RESISTANT TO ANTI-HER2 DRUGS 83
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 82
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 77
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 75
Cardio-Oncology Challenges in Elderly Patients 74
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 72
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer 69
Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232) 68
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors 67
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 67
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 66
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study 65
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. 65
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 65
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database 64
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 62
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 61
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 60
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 59
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer 59
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. 58
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study) 57
Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population 57
Malignant granular cell tumor of chest wall: a case report 55
Early Identification and Management of Patients with Rash on Apalutamide 50
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project 48
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 48
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance 46
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 44
Totale 9.083
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 0 13 6 31 27 44 29
2021/2022371 8 0 10 14 5 10 4 11 58 55 84 112
2022/2023628 63 38 31 28 69 76 15 58 88 92 42 28
2023/2024569 15 60 112 41 26 75 25 61 17 12 87 38
2024/20253.083 102 143 4 73 96 190 320 235 172 367 1.136 245
2025/20263.698 590 532 806 542 902 251 75 0 0 0 0 0
Totale 9.083